Tawfek, A., Elgharieb, M., Alnahass, H., Alnahrawy, O., Gab-Alla, A. (2022). Correlation between Diabetic Cystoid Macular Edema and Best Corrected Visual Acuity after Intravitreal Injection of Ranibizumab. Suez Canal University Medical Journal, 25(2), 7-11. doi: 10.21608/scumj.2022.223251
Ahmed Z. Tawfek; Mervat E. Elgharieb; Hussein S. Alnahass; Osama M. Alnahrawy; Amr A. Gab-Alla. "Correlation between Diabetic Cystoid Macular Edema and Best Corrected Visual Acuity after Intravitreal Injection of Ranibizumab". Suez Canal University Medical Journal, 25, 2, 2022, 7-11. doi: 10.21608/scumj.2022.223251
Tawfek, A., Elgharieb, M., Alnahass, H., Alnahrawy, O., Gab-Alla, A. (2022). 'Correlation between Diabetic Cystoid Macular Edema and Best Corrected Visual Acuity after Intravitreal Injection of Ranibizumab', Suez Canal University Medical Journal, 25(2), pp. 7-11. doi: 10.21608/scumj.2022.223251
Tawfek, A., Elgharieb, M., Alnahass, H., Alnahrawy, O., Gab-Alla, A. Correlation between Diabetic Cystoid Macular Edema and Best Corrected Visual Acuity after Intravitreal Injection of Ranibizumab. Suez Canal University Medical Journal, 2022; 25(2): 7-11. doi: 10.21608/scumj.2022.223251
Correlation between Diabetic Cystoid Macular Edema and Best Corrected Visual Acuity after Intravitreal Injection of Ranibizumab
Department of Ophthalmology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
Abstract
Background: Diabetic macular edema is a general term defined as retinal thickening within two-disc diameters of the foveal center; it can be either focal or diffuse in distribution.Intravitreal injection of anti-vascular endothelial growth factor (Ranibizumab) was approved for the treatment of diabetic macular edema. Objective:Assessment of correlation between diabetic cystoid macular edema and best-corrected visual acuity (BCVA) after intravitreal injection of Ranibizumab. Patients and Methods: Quasi-experimental interventional study was undertaken at Suez Canal University Hospital, Ophthalmology Department on patients who were diagnosed as having diabetic cystoid macular edema (CME) by optical coherence topography. A total of 60 participants were evaluated by taking a complete ophthalmologic history, examination, and investigations using a pre-designed checklist, and intravitreal injection of anti-VEGF was done. Results: Our study showed that the study group consisted of 71.4% females and 28.3% males. In our study group, we found that the Mean ± SD. In CME 3.50 ± 0.50 pre-VEGF injection, 2.0 ± 0.82 post VEGF injection with improvement1.50±0.50 (44.44%). The mean of BCVA in decimal among participants was 0.15 ± 0.06 pre-VEGF injection while 0.25 ± 0.07 post-VEGF injection with an improvement of 0.10 ± 0.03 (25.0%). There was strong relation and statistically significant. Conclusion: Intravitreal injection of anti-VEGF was very effective in diabetic macular edema. Improvement of diabetic macular edema was associated with improvement in best-corrected visual acuity.
View on SCiNiTO
Top